Coconut Creek FL - (NewMediaWire) - March 5, 2019 - NutraFuels, Inc. (the “Company”) is pleased to announce a name change to NutraLife BioSciences, Inc. and a new stock trading symbol, NLBS. The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations. Commencing March 6, 2019, the Company’s common shares will trade with the stock ticker symbol “NLBS”.The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.* These statements have not been evaluated by the Food and Drug Administration.* This product is not intended to diagnose, treat, cure or prevent any disease.Forward-Looking StatementsThis communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.Contact: NutraLife Biosciences, Inc. 6601 Lyons Road, Suite L-6 Coconut Creek, FL 33073 Telephone 888-509-8901 www.Nutralifebiosciences.com

Seattle, WA - (NewMediaWire) - March 05, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9). The company is best known for its 3.8 million square foot former Kraft Foods facility in Cobourg, Ontario, which could make it one of the largest licensed producers in the country, if approved by Health Canada. In addition to this massive footprint, the company has established many strategic alliances that have gone under-the-radar for many investors, but could generate significant long-term value.The Canadian cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, driven by the legalization of adult-use cannabis last year. With the upcoming legalization of edibles this fall, the market could significantly expand its addressable market beyond consumers willing to smoke cannabis. These dynamics could help lift the value of many different companies operating in the space.In this article, we will take a look at the company’s four strategic investments as well as other partnerships that they have in place to drive long-term shareholder value.Cannara BiotechCannara Biotech is an aspiring licensed producer that recently purchased a modern 625,000 sq. ft. facility on 27 acres of land in Quebec — less than an hour away from Montreal. In addition to owning over 85 million shares of the company, FSD Pharma will lease over 105,000 sq. ft. of the facility for the purpose of cultivating and/or selling cannabis or cannabis-derived products, creating another key venue to cultivation.SciCann TherapeuticsSciCann Therapeutics is an Israeli firm that has become one of the leaders in cannabis research. With access to its network of leading researchers, academic institutions and medical centers, FSD Pharma is free to conduct rigorous clinical studies for cannabis-based products in a highly time and cost-efficient environment. The company invested an undisclosed amount in the company for these purposes.High Tide VenturesHigh Tide Ventures is a fully-integrated retail distribution company that has applied for more than 30 retail cannabis permits in Alberta and 16 in Saskatchewan. In addition, the company plans to submit an application in British Columbia in the near-term. The company owns four of Canada’s most prominent retail brands that are poised to take advantage of the nascent recreational market. FSD Pharma made a strategic investment in the firm.Huge ShopsHuge Shops invested $1.3 million for a 9.9% ownership interest in Huge Shops, a Toronto-based cannabis retailer. The company has a strategic alliance with Chairman’s Brands/Coffee Time — a well-established operator of retail coffee shops with more than 75 locations in Canada and other locations worldwide. As part of the investment, Huge Shops has an option to acquire a minimum of ten of these retail locations.Additional PartnershipsFSD Pharma has signed several strategic partnerships aside from its four strategic investments. These partnerships include collaborations, revenue-sharing agreements, licensing agreements, and research agreements that could pay dividends over time.The company’s major partnerships include:Canntab Therapeutics: Canntab has developed patent-pending technology that provides a uniform dose of medical cannabis extract, including sustained-release options for targeted indications. Under their agreement, the company will manufacture its products in FSD Pharma’s Cobourg facility in exchange for a profit-sharing deal.World-Class Extractions: World Class has developed unique extraction processes designed to produce higher concentrations of cannabinoids, processes larger quantities, reduce production time, and utilize all parts of the plant. FSD Pharma has a license agreement in place to utilize the technology.Solarvest: FSD Pharma signed a letter of intent with Solarvest to develop and test pharma-grade cannabinoid creation from algae. The process ...

Irvine, Ca - (NewMediaWire) - March 05, 2019 - Signature Devices, Inc. (OTC PINK: SDVI), and its subsidiary Innovo Technology, today announced the official release of its Internet of Things Knoton device on both the Google app play store and iTunes app store.The Knoton is a next-generation Internet of Things device that utilizes inputs from a variety of motion sensors, ambient sensors, high-resolution cameras, and an always-connected modem. In conjunction with location GPS data and a next generation back-end AI cloud, the Knoton app and associated array of devices address the many needs in the connected device space which are currently lacking in the IoT marketplace.“With the official release of the Knoton Apps, starting with our FREE apps now available on the iTunes and Google Play store, Signature Devices, Inc. is ready to work with investors and technology enthusiasts worldwide interested in utilizing the platform for their needs,” says Inas Azzam, CEO of SDVI.One of the most important applications that the Knoton system provides is in the creation of the Knoton Emergency Notification System (ENS) which will be of enormous benefit in urgent situations especially in school settings.“The latest headlines are filled almost daily with news of horrific incidents, such as shootings, at our schools and universities which is especially depressing considering these are our places of learning,” says Mr. Azzam. “Implementation of the Knoton ENS can potentially go a long way towards minimizing the effect and scope of the tragedies at our schools,” continues Mr. Azzam.The Knoton will be able to add a layer of protection to any pre-existing school defense ecosystem by acting as an instant emergency alert system that will be able to activate a pre-alert scenario by simply pressing a button on any Knoton hardware strategically placed throughout the school locale. The Knoton ENS will provide instant pre-set text alerts to all students, faculty, administrators and just as importantly notify parents and law enforcement of the emergency.Further enhancements to the Knoton system will allow for instant E911 triggers to local law enforcement in addition to activating a loud audio signal within the school. SDVI’s refinement to the AI back end will in the future also allow for automatic activation of the Knoton ENS by utilizing algorithms that recognize say gunshot sounds. “While the Knoton will be excellent in the school setting, it will certainly not be limited to that application. Our Knoton product line will touch on the most important and sensitive aspects of people’s daily lives,” says Mr. Ghassan Elkhatib, Director of IoT Hardware and Artificial Intelligence.The Knoton technology will be applicable to a variety of situations such as with the following use cases:Child safety and tracking. The Knoton can become the ultimate family bodyguard! With its built in L5 signal based GPS motion and ambient sensors, the Knoton can react to scenarios that protect, track and interact with the child. Personal emergency and notification system. The Knoton provides the ultimate 24-7 personal security! The hardware device is easily carried or can also be installed on any iOS or Android mobile device for easy access. In case of emergency, a variety of alarms, messages, audio/video recordings, and a connection to 911 can be activated with a simple press of a button. In addition GPS location data and camera data (identified on Google map for immediate navigation), as defined by the user, can be transmitted creating the ultimate beacon!Infant monitoring and prevention of flip induced sudden death syndrome. The Knoton is the ultimate infant life-saver! The technology allows for effective monitoring of infants at home. Images and video of the infant can be analyzed locally to generate the fastest response time in case the infant flips over on their face and is unable to breathe. Facial recognition of registered perpetrators. The Knoton will be your child’s best friend! The Knoton can scan and view the surrounding of the user thereby identifying other ...

(NewMediaWire) - March 04, 2019 - DALLAS - The American Heart Association and its division, the American Stroke Association, join the chorus of organizations and individuals sending heartfelt condolences to the family, friends and fans of actor Luke Perry. Media reports indicate that Perry, age 52, died today following what has been described as a “massive stroke” on Thursday. A stroke can happen to anyone at any age, however, the risk does go up with age. "Athough stroke often affects older individuals, it is not only a disease of the elderly. Luke Perry's tragic death highlights the fact that stroke can affect middle aged and young adults, even children. In fact, there is evidence that stroke rates among young people are increasing in the United States and this requires additional research," said Mitchell S.V. Elkind M.D., M.S., chair of the American Stroke Association Advisory Committee and a professor of Neurology and Epidemiology at Columbia University and attending neurologist at Columbia University Medical Center of the NewYork-Presbyterian Hospital. "While we don't know the cause of Perry's stroke, it's important for people to know the risk factors for stroke." Those include smoking, high blood pressure, diabetes, high cholesterol, obesity and other cardiovascular diseases such as atrial fibrillation, or AFib (a heart rhythm disorder) and family history. Stroke is the No. 2 cause of death worldwide and a leading cause of disability. Many people may not know that often strokes are treatable. The faster you are treated, the more likely you are to recover. The acronym F.A.S.T. is an easy way to remember how to recognize a stroke and what to do. Spot a stroke FAST. Face drooping. Arm weakness. Speech Difficulty. Time to call 9-1-1. Stroke can be caused either by a clot obstructing the flow of blood to the brain (called an ischemic stroke) or by a blood vessel rupturing and preventing blood flow to the brain (called a hemorrhagic stroke). Treatment options depend on the type of stroke. It has not been reported what type of stroke Perry experienced. To learn more about lowering your risk for stroke, visit www.strokeassociation.org. ### About the American Heart Association The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1. About the American Stroke Association Stroke is the No. 2 cause of death worldwide and a leading cause of disability. The American Stroke Association is a relentless force for a world with fewer strokes. We team with millions of volunteers to create world of longer, healthier lives by funding innovative research, fighting for stronger public health policies, and providing lifesaving tools and information to prevent, treat and beat stroke. The Dallas-based association was created in 1998 as a division of the American Heart Association. To learn more or to get involved, call 1-888-4STROKE or visit strokeassociation.org. Follow us on Facebook and Twitter. For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173

Management Aims to Setup a World-Class Green Tech Campus in New YorkThe Company aims to harness their proprietary technology through multiple biomass processing facilities to cater to the rising demand of ethanol, carbon fibre, and other products.MILTON, GA - (NewMediaWire) - March 4, 2019 - Attis Industries (ATIS) took its first big step in the field of renewable energy when the Company acquired the ethanol production facility of Sunoco LP in Fulton, New York. Through its renewable energy vertical known as Attis Innovations, the company is working towards disrupting the fossil fuel industry by revolutionizing the processing of biomass in order to sustainably produce ethanol and other bi-products. Attis Innovations not only seeks to achieve cost advantage and profitability with their novel technologies, but to also preserve the environment via their ongoing efforts to create shared value for stakeholders. The recently acquired Fulton plant currently has the capability to produce 85 million gallons of ethanol and other products like CO2, dried distilled grains, and corn oil. The output of the Fulton plant represents Attis potentially adding over $160 million in revenues based on the following projections:· 85 Million gallons of Ethanol @ ~ $1.39 = $118,150,000· 350 Million pounds (175,000 TONS) of CO2 @ $10 per ton = $1,750,000· 480 Million pounds of Dried Distilled Grains @ $0.08 per pound = $38,400,000· 1.5M Gallons of Corn Oil @ $1.73 per gallon = $2,600,000Attis’ acquisition journey has just commenced and the management team, led by CEO Jeffery Cosman, intends to purchase additional land of approximately 300 to 400 acres near the current 134-acre Fulton facility with the goal of building a world-class green tech campus. The additional land will be used for setting up a biodiesel plant that can use the corn extract produced as a bi-product from the ethanol facility to create biodiesel. The Company also plans to establish a bio-refinery within the same campus, which will effectively result in the creation of more than 300 jobs. As of today, the management team is working towards streamlining processes and eliminating bottlenecks within the ethanol facility, which is expected to increase the output of the plant by about 20% and enable the plant to produce around 100 million gallons of ethanol each year; an increase of 15 million gallons of ethanol, which represents a projection of an additional $20 million plus of revenue. Over a long-term horizon, the management also plans to add a solar project and a wind energy project near the same site.The operations facilities of Attis Innovations are expected to be geographically diversified as the management intends to set up or acquire additional ethanol plants in other US states such as Georgia, Florida, and South Carolina over the next two years. The Company is also looking at international expansion through strategic partnerships with companies in various countries such as Malaysia, Indonesia, Philippines, Brazil, UK, Argentina, and Canada.The research and development activity of Attis is in full swing, as there are a number of potential patents in the development pipeline. The Company anticipates a very strong opportunity in the carbon fibre market, which Attis can enter through the use of its proprietary technology to extract better cellulosic value as well as lignin from biomass. The company is developing the capability to produce high-quality carbon fibre with a good tensile strength through the lignin extracted through biomass processing. Being significantly lighter and stronger than steel, carbon fibre has immense application in the automobile, aeronautical, and aerospace industries. CEO Jeff Cosman notes, “Having a significant cost advantage with respect to the production of carbon fibre through biomass is not the only benefit of Attis’ technology. We are able to produce high-quality carbon fibre without releasing more carbon into the atmosphere unlike fossil fuels. Our ways are not only more cost-effective but also more beneficial to the ...

Las Vegas, NV - (NewMediaWire) - March 04, 2019 - Golden Matrix Group Inc. (OTCPK: GMGI) a technology-driven company that designs and develops social gaming platforms, systems and gaming content, today announced that for the second fiscal quarter ended January 31, 2019, the company recorded net income of $421,791 on revenues of $713,542. This compares with net income of $84,484 on revenues of $30,000 in like year-ago quarter.Second quarter 2019 revenues and net income represent 2,278 and 399 percent increases, respectively, on revenues and net income recorded in the second quarter of 2018.For the first six months ended January 31, 2019, Golden Matrix reported net income of $753,790 on revenues of $1,352,237, compared with a net loss of $373,559 on revenues of $60,000 in the like year-ago period.Revenues recorded in the first half of fiscal 2019 were derived primarily from licensing fees received from gaming operators located in the Asia Pacific (APAC) region and integrated with the company’s state-of-the-art GM-X platform. Currently there are 192 active operators and more than 1.5 million registered users across all gaming operator/GM-X platforms.“These excellent Q2 results further demonstrate GMGI’s continued growth and success in servicing the robust Asia-Pacific gaming markets, the largest in the world,” said CEO Brian Goodman. “As previously stated, we expect the company to continue to increase market share throughout 2019 and maintain strong positive cash flow with rising profitability.”Mr. Goodman noted that cash and cash equivalents as of January 31, 2018 increased 150% to $1,118,499 from $446,581 at fiscal year-end (July 31) 2018. Total assets increased to $1,828,435, up 123% from $819,874 at fiscal year-end 2018.For additional information on Golden Matrix’s Q1 2019 performance, please refer to the Company's 10-Q filing at https://www.otcmarkets.com/stock/GMGI/disclosure or www.sec.gov.About Golden MatrixGolden Matrix Group, based in Las Vegas NV, is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers, located primarily in the Asia Pacific region. The gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company's platform can be accessed through both desktop and mobile applications.Our sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with current US law.Forward-Looking StatementsThis press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.Connect with us:Twitter - https://twitter.com/GMGI_GroupInstagram - https://www.instagram.com/goldenmatrixgroup/Golden Matrix GroupTracy Wanginfo@goldenmatrix.comTel: (702) 318-7548www.goldenmatrix.com GOLDEN MATRIX GROUP, INC Consolidated Balance ...

eHealth publishes results from survey of more than 800 short-term health insurance enrollees SANTA CLARA, Calif. , March 4, 2019 /PRNewswire/ -- A new survey of consumers who purchased short-term health ...

Vancouver, British Columbia - (NewMediaWire) - March 04, 2019 - Phyto Pharma Inc. (www.phytopharma.ca), a Vancouver, British Columbia based phytopharmaceutical and intellectual property holding company with operations in three United States jurisdictions including Colorado, California, and Puerto Rico, today announced that the Company has sold approximately $500,000 US worth of Hemp raw material to California and Colorado based labs within the month of March before the end of first quarter 2019. The Hemp raw material will be used for isolate based products for nutraceutical grade use.The Vancouver based Company contracts for the production of specific strains of high CBD biomass through strategic licensed green house and farm tolling operations based in Colorado, incorporates proprietary extraction methods for CBD oil and finally, engages in the formulation, development, and commercialization of cannabinoid-based products.Phyto Pharma brands including Phytocine™ and Rehab Rx™ are manufactured from proprietary strains of whole plant hemp extracts, containing a full spectrum of phytocannabinoids, including CBD, terpenes, flavonoids, and other valuable hemp compounds.The passage of the US 2018 Farm Bill signed by President Trump at the end of 2018 will now allow Phyto Pharma to expand its hemp biomass cultivation from raw material extraction to consumer products containing specific genetic strains and IP owned by the Company. Phyto Pharma seeks to utilize our genetic specific strains which contain high strains of cannabis derived CBD and aid in the manufacturing process specifically for pharma or nutraceutical based products for the targeted treatment of specific conditions and disease.“We are extremely pleased with the recent increase in revenue and demand for our Hemp based raw material from our Colorado farming operations. The recent orders of close to $500,000 US for the month of March alone demonstrates strong growth and demand for our proprietary extracted Hemp material to both the pharma and nutraceutical sectors. We look forward to completing the review process and recently announced acquisition by Vinergy Resources Ltd. giving us access to the public markets in both the US and Canada,” stated Phillip Johnston, Esq., CEO of Phyto Pharma Inc.Legalization and acceptance of CBD for its health and wellness benefits is accelerating at a rapid pace globally. CBD is presently most commonly being used for anxiety, insomnia, pain and nausea, but is being investigated as a treatment for other conditions. Earlier this year, the U.S. FDA approved the CBD drug, Epidiolex, for the treatment of childhood epilepsy. The World Health Organization has also recommended descheduling CBD as a controlled substance among its 194-member states. The Brightfield Group of Chicago forecasts the market for CBD from hemp could reach US$22 billion by 2022.Phyto Pharma is not making specific therapeutic claims. The use of the term pharmaceutical, pharmaceutical grade, pharmaceutical dosage forms, etc. are indicative of the process by which new formulation products will be created with the intent of accurately identifying specific strains, the active ingredients and measured amount to be used in each dosage form using best practices associated with traditional pharmacy formulations. Phyto Pharma is seeking to take existing anecdotal evidence and through its own formulation process further identify which cannabis varieties and strains are best suited to aid in a specific disease. The goal is to provide a reliable clinical effect through the use of well-crafted and well-researched oil analytics and dosage forms including oral and transdermal delivery of IP mapped cannabis extracts and nutraceutical and pharma brands.About Phyto Pharma Inc.Phyto Pharma Inc. (www.Phytopharma.ca) is a phytopharmaceutical and intellectual property holding company that has been created to develop innovative cannabis products, using accepted pharmaceutical formulation techniques, to reliably produce identifiable and replicable dosage forms for the targeted treatment of ...

Supported by Contract from U.S. Agency for International Development (USAID)Atlanta, GA - (NewMediaWire) - March 04, 2019 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it has expanded its collaboration activities with Leidos, Inc. to develop malaria vaccine candidates. The work will be supported under a contract to Leidos from the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP). Leidos has been tasked by USAID to advance promising vaccine candidates against P. falciparum malaria and selected the GeoVax MVA-VLP platform as part of this development effort.GeoVax’s vaccine technology is based on its live Modified Vaccinia Ankara (MVA) platform, which generates vaccine antigens, in the form of multimeric proteins or noninfectious VLPs, in the individual being vaccinated. Gene sequences of target antigens are inserted into the MVA genome which drives their expression and budding from the infected cells. In this way, vaccination strategy mimics a natural viral infection which induces two pools of proteins – virus-infected cells and released multimeric or VLP proteins.Farshad Guirakhoo, PhD, GeoVax’s Chief Scientific Officer, commented, “Currently there is a shortage of malaria vaccine candidates that can offer the high efficacy rates (e.g. >75%) set by the World Health Organization (WHO) as a requirement for the second-generation malaria vaccines. Although protein-derived vaccines can deliver multiple antigens in immunogenic VLP conformation, they hardly produce a balanced functional cellular immune response needed to confer a high protection. In contrast, vectored-derived live vaccines are capable of producing the appropriate balanced immune responses, but they suffer from limitations in delivering the required number of transgenes needed to protect against all stages of malaria parasite. GeoVax’s MVA-VLP platform can overcome both limitations of antigen conformation and transgene capacity by delivering multiple transgenes (e.g. from parasite’s liver stage, blood stage and mosquito stage) in the form of VLPs delivered in vivo. This new collaboration with Leidos complements our ongoing malaria vaccine development project with Burnet Institute in Australia and offers multiple opportunities for success.”David Dodd, GeoVax’s President and CEO, said, “We are delighted to broaden our relationship with Leidos to include malaria vaccines. This remains a significant unmet healthcare need and we believe that this collaboration has the potential to result in a significant improvement in this critical area. Our hope is to successfully proceed through product development and identify promising vaccine candidates that can be taken into clinical development as quickly as possible, demonstrating an effective, safe vaccine for malaria prevention. We are confident that our technology, combined with Leidos' has an excellent chance for success.”About GeoVaxGeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, as well as a finalist for Pipelines of Promise at Buzz of Bio 2018. The Company’s development programs are focused on vaccines against HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa) and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax’s vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, ...

Company Books Additional 41 Franchise Commitments for $2,238,000 in Deferred Revenues and Secures 47 New Locations for its Franchisees and 19 Degrees Fund SAN DIEGO, CA - (NewMediaWire) - March 04, 2019 - Generation NEXT Franchise Brands, Inc. (OTCQB: VEND) announced its monthly report to stakeholders for the month of February today. The report is part of a continued effort announced last month to keep all Company stakeholders better informed of key operating metrics and in a transparent environment. Key highlights and metrics for February: Booked 41 new Reis secured 78 locations which are scheduled for installation between April and June 2019.“We’ve received positive reports from our franchisees and locations about the performance of Reis & Irvy’s during February,” said Nick Yates, CEO of Generation Next Franchise Brands. “Our engineering solutions and manufacturing improvements are having the impact we expected. Our month-over-month results will continue to improve as we finish upgrading existing kiosks and gradually increase the pace of our new robot installations.” Generation Next and its franchisees discovered defects in the first batch of kiosks assembled and installed during the second half of calendar year 2018, resulting in a production halt that persisted until late February, when the Company resumed kiosk production and began upgrading existing kiosks with redesigned hardware and software. February installation numbers were negatively impacted as a result of this production halt.Yates recently received this note from a Houston franchisee regarding the upgrades: “Nick, Improvements have been observed in recent testing of the 0.71 software, along with Stoelting firmware updates, on one of our machines with a history of HVB Errors. We have been monitoring consistencies and temperature cycles as compressors cool the cylinders and then the hoppers, all working as would be expected. The units do not seem to be over-working, as they were in the past. This appears to be a good collaboration between Stoelting and ReThink. Thanks! Regards, Michael and Michelle Bingham” From March through June 2019, the Company estimates it will install an additional 100 to 150 robots bringing the total robots installed for the fiscal year ended June 30, 2019 to between 290 and 340 with annual revenue recognized of $11.0 to $12.9 million. From July to December 2019, Generation Next expects to install 600 to 800 additional robots and recognize between $22.8 and $30.4 million in revenue. For more information, visit the Reis & Irvy’s website at www.reisandirvys.com or call Toll-Free (888) 902-7558. Generation NEXT Website: www.gennextbrands.com About Generation NEXT Franchise Brands, Inc. Generation NEXT Franchise Brands, Inc., based in San Diego, California, is a publicly traded company on the OTC Markets trading under the symbol OTCBB: VEND. Generation NEXT Franchise Brands, Inc. is parent company to Reis and Irvy’s Inc and 19 Degrees Corporate Service LLC About Reis & Irvy’s, Inc. Reis & Irvy’s, Inc. is a subsidiary franchise concept of Generation NEXT Franchise ...